View in Other Languages

Medibio Ltd

ASX:MEB ISIN:AU000000MEB8

Medibio Ltd ASX MEBMedibio Ltd (ASX:MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.

  

News

Medibio Ltd (ASX:MEB) Breakthrough Validation of Algorithm for Diagnosing Depression Using Independent Clinical Data

🕔8/8/2016 2:10:32 PM 7802

Medibio Ltd (ASX:MEB) is pleased to announce that it has successfully undertaken validation of its depression classification algorithm using retrospective data sourced in partnership with The University of Ottawa. This validation is a significant milestone in the Company's development of a proprietary objective test for the diagnosis of depression.

Read Full Article

Australian Market Report of July 29: US Consumer Confidence Falls

🕔7/29/2009 1:00:26 PM 12299

US stocks closed flat overnight after a weaker-than-expected survey on consumer confidence. The Conference Board reported its confidence index fell to 46.6 from 49.3 in June, primarily due to a worsening job market.

Read Full Article

Bioprospect Limited ASX: BPO - Farm-in Agreement with Solagran - Mr Warwick Dowse, MD

🕔4/16/2007 5:43:00 PM 5432

Bioprospect Limited (ASX: BPO) - Farm-in Agreement with Solagran - Mr Warwick Dowse, MD; Boardroomradio is pleased to announce that Bioprospect Limited (ASX: BPO) has published an audio file.

Read Full Article
###

45,362 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 12) (Last 30 Days: 48) (Since Published: 8096) 

Company Data

    Headquarters
  • Suite 605
    Level 6 50 Clarence Street
    Sydney, NSW 2000
    Australia
  • Telephone
  • +61-2-9299-9580 
  • Fax
  • +61-2-9299-9501 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.medibio.com.au

Social Media